A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms ATLAS
- Sponsors Sanofi
- 11 Mar 2024 Planned End Date changed from 18 Jan 2028 to 22 Jan 2030.
- 11 Mar 2024 Planned primary completion date changed from 28 Jun 2025 to 31 Oct 2029.
- 28 Nov 2023 Planned End Date changed from 15 Oct 2027 to 18 Jan 2028.